NICE recommends three diabetes treatments

25 May 2016

The National Institute for Health and Clinical Excellence (NICE), the medicines cost-effectiveness watchdog for England and Wales, has today published final guidance recommending three drugs for treating type 2 diabetes.

The three drugs can all be used on their own if a person can’t use metformin or other specific drugs, and diet and exercise alone isn’t controlling their blood glucose levels.

The three drugs considered in this appraisal are: canagliflozin (Invokana, from Johnson & Johnson [NYSE: JNJ] subsidiary Janssen), dapagliflozin (Forxiga, from AstraZeneca [LSE: AZN]) and empagliflozin (Jardiance, from Boehringer Ingelheim and Eli Lilly [NYSE: LLY]). The drugs are all selective sodium-glucose co-transporter 2 (SGLT-2) inhibitors, which block the reabsorption of glucose in the kidneys and promote excretion of excess glucose in the urine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK